Keyword Analysis & Research: ibudilast ms


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
ibudilast ms1.790.492807412
ibudilast0.190.69397879
ms0.990.68227552

Keyword Research: People who searched ibudilast ms also searched

Keyword CPC PCC Volume Score
ibudilast ms1.470.1914458
ibudilast msds0.190.889448
ibudilast primary progressive ms0.950.6428051
ibudilast progressive ms1.20.620373
ibudilast multiple sclerose1.130.5389770

Search Results related to ibudilast ms on Search Engine

  • Ibudilast in MS | Experimental MS Treatments | Multiple Sclerosis

    multiplesclerosisnewstoday.com

    https://multiplesclerosisnewstoday.com/ibudilast-mn-166-multiple-sclerosis/

    WEBJun 10, 2022 · Administration. Clinical trials. Side effects. FAQs. What is ibudilast for MS? Ibudilast (MN-166) is an orally available small molecule that is being developed for the treatment of relapsing and...

    DA: 50 PA: 81 MOZ Rank: 34

  • Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1803583

    WEBAug 29, 2018 · There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor...

    DA: 61 PA: 91 MOZ Rank: 3

  • Phase 3 Trial of Ibudilast in Secondary Progressive MS Being …

    multiplesclerosisnewstoday.com

    https://multiplesclerosisnewstoday.com/news-posts/2021/08/19/medicinova-planning-phase-3-ibudilast-trial-secondary-progressive-ms/

    WEBAug 19, 2021 · Ibudilast, MediciNova, MN-166, secondary progressive MS. The Phase 3 trial, in early planning stages, will access oral ibudilast's potential to slow progression in SPMS patients without...

    DA: 14 PA: 69 MOZ Rank: 52

  • MS Minute: Ibudilast - Practical Neurology

    practicalneurology.com

    https://practicalneurology.com/articles/2020-jan/ms-minute-ibudilast

    WEBMS Minute: Ibudilast. Ibudilast is a phosphodiesterase inhibitor that has shown some benefit for progressive multiple sclerosis in a phase 2 trial. Abdul R. Alchaki, MD; and Andrew D. Goodman, MD. View/Print PDF View References. What is Ibudilast?

    DA: 90 PA: 95 MOZ Rank: 28

  • Ibudilast found to slow growth of chronic brain lesions in MS in trial

    multiplesclerosisnewstoday.com

    https://multiplesclerosisnewstoday.com/news-posts/2024/02/01/ibudilast-slows-growth-chronic-brain-lesions-progressive-ms-trial/

    WEBFeb 1, 2024 · Use of oral ibudilast — being explored as a treatment for progressive forms of multiple sclerosis (MS) — was found to significantly slow the growth of chronic active lesions in the brains...

    DA: 2 PA: 72 MOZ Rank: 40


  • The role of glial cells in multiple sclerosis disease progression

    nature.com

    https://www.nature.com/articles/s41582-022-00624-x

    WEBFeb 21, 2022 · In a trial of ibudilast in progressive MS, treatment slowed brain volume loss over a 96-week period without affecting relapse activity 123. Microglia — the future

    DA: 34 PA: 100 MOZ Rank: 11

  • Ibudilast | Neurology

    neurology.org

    https://www.neurology.org/doi/10.1212/WNL.0000000000011312

    WEBDec 2, 2020 · Ibudilast is a drug that has previously been suggested to have a neuroprotective effect in relapsing-remitting MS 1: ibudilast (60 mg) did not reduce the MRI activity or the relapse rate but reduced brain volume loss accumulation by 34%.

    DA: 91 PA: 77 MOZ Rank: 58

  • Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

    nejm.org

    https://www.nejm.org/doi/pdf/10.1056/NEJMoa1803583?articleTools=true

    WEBIn a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associ-ated with higher rates...

    DA: 63 PA: 31 MOZ Rank: 43

  • Ibudilast for the treatment of multiple sclerosis - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/27501293/

    WEBIbudilast is a nonselective phosphodiesterase inhibitor which works by blocking the cleavage of cyclic adenosine monophosphate (cAMP). It has been found to have anti-inflammatory and neuroprotective properties in animal studies and in-vitro studies; it is currently being studied in progressive MS.

    DA: 26 PA: 52 MOZ Rank: 32

  • Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/30157388/

    WEBAug 30, 2018 · Conclusions: In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal …

    DA: 9 PA: 44 MOZ Rank: 26